Products - Lung cancer | Topic

Showing 135 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 December 2024
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 November 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2023
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2023
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 June 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) (TA884)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 May 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2023
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2022
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 August 2022
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2022
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 May 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 January 2022
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 January 2022
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 September 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 June 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2021
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 October 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 May 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2020
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 August 2019
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 July 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 May 2018
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2018
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
11 January 2017
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
10 August 2017
Published:
23 June 2010
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 March 2017
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2017
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2015
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 October 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2011
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2009
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 September 2009
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2007
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
19 February 2025
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 April 2025
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 April 2025
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 July 2025
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 July 2025
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 August 2025
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 September 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treatments for non-small-cell lung cancer [ID6234]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations TSID 12011
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy TS ID 12115
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years TS ID 12116
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Lung cancer Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 135 products

Guidance programme
1 selected